PsyBio continues to develop psycho-targeted, biosynthesized tryptamines and with this authorization becomes the first biotechnology company to obtain government sanctioned, formal, written authorization to manufacture biosynthetic tryptamines including PsyBio-11142 at scale Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - July 21, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company... Read More

Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - April 20, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that the Company has completed the third... Read More

Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - April 6, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that PsyBio CEO Evan Levine will be... Read More

Prestigious award recognizes innovative company as a leading player in the emerging field of psychedelic medicine Miami, Florida--(Newsfile Corp. - March 13, 2023) - Evan Levine, CEO and Founder of PsyBio Therapeutics , won Best Pitch at Kahner Global's Cannabis & Psychedelics Investment Summit last week. Levine was awarded for his visionary approach to developing next-generation therapies for mental health conditions using... Read More

Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - January 13, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that the Company has completed the second... Read More

Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - January 10, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual property driven biotechnology company focused on the discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce the addition of life sciences veteran Ian... Read More

Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - January 5, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that the Company has completed the first... Read More

PsyBio continues to demonstrate its Environmental, Social, and Governance (ESG) commitment while increasing its presence in the psycho-targeted biosynthesis intellectual property space and remains strongly committed to innovation, development, and technology optimization OXFORD, Ohio and DENVER , Dec. 8, 2022 /CNW/ - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual... Read More

PsyBio continues to increase its presence in the psycho-targeted biosynthesis intellectual property space and remains strongly committed to innovation, development, and technology optimization OXFORD, OH and DENVER , Dec. 6, 2022 /CNW/ - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual property driven biotechnology company focused upon discovery and development of new,... Read More

OXFORD, Ohio and DENVER , Dec. 1, 2022 /CNW/ - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual property driven biotechnology company focused on discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, announces that it intends to complete a non-brokered private placement of up to 20,000,000 units of... Read More

PsyBio continues towards understanding psycho-targeted, biosynthesized tryptamines and remains strongly committed to innovation, development, and technology optimization demonstrated by the desire to advance compounds into clinical trials PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual property driven biotechnology company focused upon discovery and development of novel,... Read More

PsyBio continues to increase its presence in the psycho-targeted biosynthesis intellectual property space and remains strongly committed to innovation, development, and technology optimization PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to... Read More

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announces that Evan Levine , Chief Executive Officer and Chairman, will present at the... Read More

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announced that it has reported its unaudited interim financial results for the three and... Read More

Biosynthetic Production covers Methylated Tryptamine Derivatives including DMT and 5-MeO-DMT PsyBio Therapeutics Corp. (TSXV: PSYB), (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual property driven biotechnology company focused upon discovery and development of novel, psycho-targeted therapeutics to potentially improve mental and neurological health, today is announcing the filing of data to support the... Read More

PsyBio is continuing to increase its psycho-targeted patent portfolio, executing on its strategic priorities of innovation, development, and technology optimization PsyBio now has twenty patent applications in total PsyBio Therapeutics Corp . (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke,... Read More

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), announces that it will be hosting its annual general and special meeting of shareholders (the " Meeting ") virtually at 11:00 am Eastern Time on Thursday , August 11, 2022, as further detailed in proxy materials being distributed to shareholders, which will be available under the Company's profile on SEDAR at www.sedar.com . At the... Read More

PsyBio Therapeutics Advances Proprietary Patent Pending Manufacturing Towards Fully Developed GMP Production Methodology PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders... Read More

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announced that it has reported its interim financial results for the three month... Read More

PsyBio Therapeutics Further Expands Scalable Manufacturing Process Development PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today... Read More

PsyBio Therapeutics Further Expands Testing of Portfolio Compounds PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of... Read More

PsyBio Therapeutics further extends and expands intellectual property protection PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today... Read More

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health... Read More

PsyBio Therapeutics is developing a network of highly qualified, local principal investigators to recruit and conduct upcoming clinical trials PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an integrated and intellectual property driven biotechnology company developing novel, bespoke... Read More

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an integrated and intellectual property driven biotechnology company focusing on discovering developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders... Read More

PsyBio Therapeutics to Make Significant Environmental, Social, and Governance (ESG) Commitment to Promote Mental and Neurological Health While Working to Develop State of the Art Technologies, Process Skills and Capabilities in Lesotho and Across Africa PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the "... Read More